FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:961 August 31, 2006 Number 9 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Whitcomb, D. C. PubMed Citation

To the Editor: In his article on acute pancreatitis, Whitcomb (May 18 issue)¹ does not mention the debate about the use of protease inhibitors, such as gabexate, as prophylaxis for pancreatitis induced by endoscopic retrograde cholangiopancreatography (ERCP), a potentially severe complication that occurs in up to 13.5 percent of patients undergoing the procedure. A recent meta-analysis by Seta et al.² showed that the use of protease inhibitors significantly reduced the rate of death in moderate-to-severe pancreatitis. This finding indicates that gabexate should routinely be added to the usual standard of care, at least for patients who are more severely affected . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.